Lupin gets USFDA nod for generic hypertension drug

PTI New Delhi | Updated on March 22, 2013 Published on March 22, 2013

Drug major Lupin today said it has received US health regulator’s approval to market generic version of Novartis Pharmaceuticals Corp’s Diovan HCT Tablets, a hypertension drug, in the American market.

Lupin Pharmaceuticals Inc, a subsidiary of Lupin Ltd, has received approval from the US Food and Drug Administration (USFDA) for its Valsartan and Hydrochlorothiazide Tablets (HCT), Lupin Ltd said in a statement.

The Mumbai-based firm said it has already commenced shipping the product.

Lupin’s Valsartan and Hydrochlorothiazide Tablets USP are indicated for the treatment of hypertension, to lower blood pressure.

According to IMS MAT Sept 2012 sales data, Valsartan and Hydrochlorothiazide Tablets had sales of around $1.7 billion in the US market.

The stock of Lupin today closed at Rs 627.85 per share on the BSE, up 0.75 per cent from its previous close.

Published on March 22, 2013
This article is closed for comments.
Please Email the Editor